title: [Clinical effects of a combination treatment with cefodizime and minocycline for infections in patients complicated with hematological disorders].
abstract: We evaluated clinical effects and toxicities of a combination in treatment with cefodizime (CDZM) and minocycline (MINO) for infections complicated with hematological disorders in 67 patients. Fifty-nine patients were evaluable, including 32 with acute leukemia, 15 with malignant lymphoma, and 12 with other hematological disorders. Clinical efficacies were excellent in 17 cases, good in 24 cases, fair in 2 cases, and poor in 16 cases. The efficacy rate was 69.5% (41 cases/59 cases). This treatment was also effective in 8 of 12 cases in which granulocyte counts were less than 500/microliter through the course of administration. No subjective side effects were observed. Abnormal values in laboratory tests were noted in 5 cases. Mild elevations of GOT, GPT, Al-P and bilirubin were observed, but none was serious. Thus, the combination of CDZM and MINO is an effective and safe regimen for the treatment of infections in patients complicated with hematological disorders.
authors.affiliation: Third Department of Medicine, Kyoto Prefectural University of Medicine.
authors.forename: K
authors.initials: K
authors.lastname: Hirakawa
authors.forename: S
authors.initials: S
authors.lastname: Tsuda
authors.forename: S
authors.initials: S
authors.lastname: Misawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kuzuyama
authors.forename: H
authors.initials: H
authors.lastname: Nakai
authors.forename: T
authors.initials: T
authors.lastname: Seriu
authors.forename: T
authors.initials: T
authors.lastname: Takashima
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
authors.forename: H
authors.initials: H
authors.lastname: Nishigaki
authors.forename: S
authors.initials: S
authors.lastname: Yokota
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000410:Alanine Transaminase; D001219:Aspartate Aminotransferases; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D002439:Cefotaxime / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D008911:Minocycline; D002439:Cefotaxime; C033356:cefodizime